Asset profile
Disitamab Vedotin
Antibody–drug conjugate
Phase 3underway
Evidence outlook · registrational
HR+/HER2- Metastatic Breast Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2027-12-31.
NCT03052634: The study was non-randomized, open-label, and had no comparator arm; all participants received disitamab vedotin at one of several doses. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Also in development:Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
129 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication; 83 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Disitamab Vedotin: this drug | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | ||
| Zanidatamab | Approved | Multispecific antibody | HER2 | ||
| Zongertinib | Approved | Small molecule | HER2, HER2 Mutant-selective | ||
| BL-M07D1 | Phase 3 | Antibody–drug conjugate | HER2 | ||
| DB-1303 | Phase 3 | Monoclonal antibody | HER2 | ||
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Tucatinib | Phase 3 | Small molecule | HER2 | ||
| HRS-4508 | Phase 2 | Small molecule | HER2 | ||
| 177Lu-DWJ155 | Phase 1 | Radiopharmaceutical | HER2 | ||
| BL-M17D1 | Phase 1 | Antibody–drug conjugate | HER2 | ||
| KJ015 | Phase 1 | Monoclonal antibody | HER2 | ||
| MT-304 | Phase 1 | Cell therapy | HER2 | ||
| NVL-330 | Phase 1 | Small molecule | HER2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 |
…and 114 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Trastuzumab Deruxtecan · Non-Small Cell Lung Cancer +1vs Zanidatamab · Non-Small Cell Lung Cancervs Zongertinib · Non-Small Cell Lung Cancervs BL-M07D1 · Non-Small Cell Lung Cancervs DB-1303 · HR+/HER2- Metastatic Breast Cancervs Trastuzumab rezetecan · Non-Small Cell Lung Cancer +1
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(56 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
December 2026 (7)
Phase 2/3Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05831878 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-06 · NCT07446452 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-11 · NCT04879329 · CT.gov ↗
What to watch
Phase 2HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06730373 · CT.gov ↗
What to watch
Phase 3Urothelial Carcinoma, HER2-expressingRecruiting
Est. primary completion 2026-12-31 · NCT05302284 · CT.gov ↗
What to watch
2027 (26)
January 2027 (5)
Phase 2Paget Disease, Extramammary, Scrotum DiseaseRecruiting
Est. primary completion 2027-01 · NCT06791070 · CT.gov ↗
What to watch
Phase 2Advanced Urothelial Carcinoma, Probiotics, ImmunotherapyRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, HER2Recruiting
Est. primary completion 2027-01-04 · NCT07285941 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-29 · NCT05911295 · CT.gov ↗
What to watch
Phase 2Upper Urinary Tract Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-01-31 · NCT07591805 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Recurrent Cervical CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07172217 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Non-Muscle-Invasive Bladder Cancer (NMIBC)Recruiting
Est. primary completion 2027-04 · NCT07646145 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-05-17 · NCT06420973 · CT.gov ↗
What to watch
Phase 1/2Prostate Cancer, CDK12 Gene MutationRecruiting
Est. primary completion 2027-05-31 · NCT06663007 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (2)
August 2027 (2)
September 2027 (1)
Phase 2Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-09-01 · NCT06560528 · CT.gov ↗
What to watch
October 2027 (2)
December 2027 (8)
Phase 2Carcinoma, Upper Tract Urothelial Carcinoma, UTUCRecruiting
Est. primary completion 2027-12 · NCT05917158 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Phase 2Muscle-invasive Bladder Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-10 · NCT07279597 · CT.gov ↗
What to watch
Phase 2Extramammary Paget Disease, Scrotum DiseaseRecruiting
Est. primary completion 2027-12-30 · NCT07117851 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer Metastatic, Ovarian Cancer Metastatic RecurrentRecruiting
Est. primary completion 2027-12-30 · NCT07311577 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07201675 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07584733 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT04400695 · CT.gov ↗
What to watch
2028 (13)
January 2028 (1)
Phase 2/3HER2-positive Breast Cancer, Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-16 · NCT07366840 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-01 · NCT05904964 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Gastric AdenocarcinomaNot yet recruiting
Est. primary completion 2028-04-30 · NCT07507526 · CT.gov ↗
What to watch
May 2028 (3)
Phase 3Gastric CarcinomaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
Phase 2Upper Urinary Tract Urothelial CarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT06210490 · CT.gov ↗
What to watch
Phase 2HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBTNot yet recruiting
Est. primary completion 2028-05-31 · NCT07100184 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06 · NCT07490990 · CT.gov ↗
What to watch
Phase 2Bladder Urothelial Carcinoma, Bladder CancerRecruiting
Est. primary completion 2028-06-30 · NCT07717242 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Ovary CancerRecruiting
Est. primary completion 2028-08-01 · NCT06540729 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-09-30 · NCT07194005 · CT.gov ↗
What to watch
December 2028 (1)
2029 (6)
March 2029 (1)
Phase 1/2High-risk Non-muscle Invasive Bladder CancerRecruiting
Est. primary completion 2029-03-15 · NCT06378242 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2029-04-10 · NCT07509424 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Upper Tract Urothelial CarcinomaRecruiting
Est. primary completion 2029-05-01 · NCT07498907 · CT.gov ↗
What to watch
June 2029 (2)
July 2029 (1)
Phase 2Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms …Active not recruiting
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 2/3Urinary Bladder NeoplasmsNot yet recruiting
Est. primary completion 2030-06-30 · NCT07608224 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2031-03-31 · NCT07474064 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting
Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗
What to watch
December 2031 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2031-12-31 · NCT06417554 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.